Holen Sie sich die Stockscreener-App
24.81
7.54%
1.74
Handel nachbörslich:
24.33
-0.48
-1.93%
Schlusskurs vom Vortag:
$23.07
Offen:
$23.47
24-Stunden-Volumen:
1.85M
Relative Volume:
0.65
Marktkapitalisierung:
$3.16B
Einnahmen:
$24.05M
Nettoeinkommen (Verlust:
$-243.33M
KGV:
-8.2689
EPS:
-3.0004
Netto-Cashflow:
$-370.18M
1W Leistung:
-2.40%
1M Leistung:
-15.58%
6M Leistung:
+521.80%
1J Leistung:
+520.25%
1-Tages-Spanne:
$23.44
$24.94
1-Wochen-Bereich:
$22.08
$25.71
52-Wochen-Spanne:
$2.7601
$30.60
Alumis Inc Stock (ALMS) Company Profile
Firmenname
Alumis Inc
Sektor
Branche
Telefon
650-231-6625
Adresse
280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALMS vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALMS
Alumis Inc
|
24.81 | 2.93B | 24.05M | -243.33M | -370.18M | -3.0004 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Alumis Inc Stock (ALMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-11 | Eingeleitet | Raymond James | Strong Buy |
| 2026-02-25 | Eingeleitet | Stifel | Buy |
| 2026-01-21 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-07-25 | Eingeleitet | Wells Fargo | Overweight |
| 2025-06-10 | Fortgesetzt | Guggenheim | Buy |
| 2025-01-30 | Eingeleitet | Oppenheimer | Outperform |
| 2024-10-31 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-10-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-07-23 | Eingeleitet | Guggenheim | Buy |
| 2024-07-23 | Eingeleitet | Leerink Partners | Outperform |
| 2024-07-23 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Alumis Inc Aktie (ALMS) Neueste Nachrichten
Alumis: Oral Psoriasis Med Can Win Approval, Challenge Big Pharma In Major Markets (ALMS) - Seeking Alpha
Why Alumis Inc. Shares Are Surging Today - TipRanks
Alumis (NASDAQ:ALMS) Shares Down 5.8%Here's What Happened - MarketBeat
Why Alumis Inc. Stock Is Suddenly Sinking - TipRanks
Aug PostEarnings: Can Alumis Inc ride the EV wave2026 Highlights & Reliable Volume Spike Alerts - baoquankhu1.vn
Chardan Capital initiates coverage of Alumis (ALMS) with buy recommendation - MSN
Alumis Inc. (ALMS) Receives a Buy from Morgan Stanley - The Globe and Mail
Short Covering: Is Alumis Inc gaining market shareJobs Report & Technical Analysis for Trade Confirmation - baoquankhu1.vn
Alumis (ALMS) Q4 Loss Of US$92.9 Million Tests Bullish Growth Narrative - simplywall.st
Alumis (ALMS) Sees Price Target Raised by Morgan Stanley | ALMS Stock News - GuruFocus
Alumis (NASDAQ:ALMS) Price Target Raised to $38.00 - MarketBeat
Alumis (NASDAQ:ALMS) Given New $38.00 Price Target at Chardan Capital - MarketBeat
Alumis Reports Positive Phase 3 Results for Envudeucitinib in Psoriasis, Financial Highlights, and 2026 Milestones - Minichart
ALMS Stock Chart | ALUMIS INC (NASDAQ:ALMS) - ChartMill
Alumis (NASDAQ:ALMS) Issues Quarterly Earnings Results - MarketBeat
[S-3ASR] ALUMIS INC. SEC Filing - Stock Titan
Alumis : Corporate PresentationMarch 2026 - marketscreener.com
Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements - The Manila Times
Alumis 2025 10-K: $24.05M revenue, $(2.86) EPS (loss) - TradingView
Alumis (NASDAQ: ALMS) advances TYK2 pipeline and closes $238M ACELYRIN stock merger - Stock Titan
Alumis (ALMS) details 2025 results, envudeucitinib NDA plan and cash raise - Stock Titan
A psoriasis pill hit late-stage goals; Alumis plans U.S. filing in 2026 - Stock Titan
ALMS Earnings History & Surprises | EPS & Revenue Results | ALUMIS INC (NASDAQ:ALMS) - ChartMill
Alumis presents phase 3 psoriasis trial data at dermatology meeting By Investing.com - Investing.com India
**Key Clinical Data to Be Revealed Soon** Biopharmaceutical company Alumis Inc. announced that the phase III clinical trial data of its lead candidate drug Envudeucitinib for the treatment of moderate-to-severe plaque psoriasis has been selected for the "Lat - Bitget
**Key Clinical Data to Be Revealed Soon** Biopharmaceutical company Alumis Inc. announced that the phase III clinical trial data of its lead candidate drug Envudeucitinib for the treatment of moderate to severe plaque psoriasis has been selected for the "Lat - Bitget
Alumis presents phase 3 psoriasis trial data at dermatology meeting - Investing.com
Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting - The Manila Times
Experimental oral psoriasis drug’s Phase 3 results to debut at skin conference - Stock Titan
Huge insider buying now at this insurance giant and 2 biotechs - MSN
Alumis (NASDAQ:ALMS) Trading Down 3.5%Here's What Happened - MarketBeat
ALMS Technical Analysis & Stock Price Forecast - Intellectia AI
Wells Fargo Initiates Coverage of Alumis (ALMS) with Overweight Recommendation - MSN
Alumis Inc. (NASDAQ:ALMS) Sees Significant Drop in Short Interest - MarketBeat
Alumis Inc. (ALMS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Alumis Inc expected to post a loss of 98 cents a shareEarnings Preview - TradingView
Inflation Data: Can Alumis Inc ride the EV waveGold Moves & Low Risk Investment Opportunities - baoquankhu1.vn
Raymond James initiates coverage of Alumis (ALMS) with strong buy recommendation - MSN
Raymond James Starts ALMS (Alumis Inc. Common Stock) at Strong Buy Mar 2026 - Meyka
Alumis (NASDAQ:ALMS) Stock Price Down 6.7%Should You Sell? - MarketBeat
This Ligand Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday - Benzinga
Alumis (ALMS) to Release Earnings on Wednesday - MarketBeat
Assessing Alumis (ALMS) Valuation After A Strong Multi‑Month Share Price Run - Yahoo Finance
Raymond James initiates Alumis stock coverage citing psoriasis drug potential - Investing.com Nigeria
Raymond James initiates Alumis stock coverage citing psoriasis drug potential By Investing.com - Investing.com South Africa
Alumis Teases TYK2 Catalysts at Leerink: Phase III Psoriasis Wins, NDA Plan and Lupus Readout Ahead - Yahoo Finance
TYK2 Validation and Expanding Indications Drive Buy Rating and $40 Price Target for Alumis - TipRanks
Certain Options of Alumis Inc. are subject to a Lock-Up Agreement Ending on 9-MAR-2026. - marketscreener.com
Phase III wins lift Alumis, Corcept shares in January - bioworld.com
Alumis to Present at the Leerink Partners Global Healthcare Conference - The Manila Times
ALMS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Finanzdaten der Alumis Inc-Aktie (ALMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):